AstraZeneca

AZN

Cambridge, United Kingdom· Est. 1999

astrazeneca.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AZN · Stock Price

USD 182.52+47.38 (+35.06%)

Market Cap: $282.1B

Historical price data

Market Cap: $282.1BPipeline: 200 drugs (26 Phase 3)Patents: 20Founded: 1999Employees: Approximately 80,000HQ: Cambridge, United Kingdom

Sector Ranking#29 in Small Molecule Drugs #2 in AI / Machine Learning

Overview

AstraZeneca is a global biopharmaceutical leader with a mission to push the boundaries of science to deliver life-changing medicines. The company has achieved significant commercial success with 16 blockbuster drugs and a robust pipeline of 197 projects, underpinned by a 'Growth Through Innovation' strategy focused on disease biology, next-generation therapeutics, predictive clinical success, and clinical innovation. AstraZeneca's strategic integration of data science, AI, and novel therapeutic modalities positions it to maintain its competitive edge and address complex healthcare challenges across its core therapeutic areas.

OncologyCardiovascular/Renal/MetabolicRespiratory & ImmunologyRare DiseaseVaccines & Immune Therapies

Technology Platform

An integrated ecosystem built on four pillars: deep disease biology understanding via genomics & AI-powered knowledge graphs; next-generation therapeutics (oligonucleotides, cell therapy, peptides, etc.); predictive clinical success using human-relevant models; and horizontal application of data science & AI across R&D.

Pipeline

200

200 drugs in pipeline26 in Phase 3

Drug	Indication	Stage
Dapagliflozin + Placebo matching with Dapagliflozin + Saxagl...	Type 2 Diabetes	Phase 3
Ciclesonide + Placebo	Asthma	Phase 3
Dapagliflozin + Dapagliflozin + Placebo matching Dapaglifloz...	Type 2 Diabetes	Phase 3
Tesaglitazar	Type 2 Diabetes	Phase 3
Datopotamab deruxtecan + Durvalumab + Carboplatin + Pembroli...	NSCLC	Phase 3

Funding History

IPOUndisclosedUndisclosedApr 6, 1993

FDA Approved Drugs

KOSELUGONDASep 10, 2025

WAINUA (AUTOINJECTOR)NDADec 21, 2023

TRUQAPNDANov 16, 2023

Opportunities

Significant near-term growth is driven by a wave of late-stage pipeline readouts and potential launches across core therapy areas, particularly in oncology and rare diseases.

Long-term opportunities are anchored in the company's leadership in AI-driven discovery and next-generation modalities like cell therapy and mRNA, which could redefine treatment paradigms.

Risk Factors

Key risks include clinical trial failures for high-value pipeline assets, intensifying pricing and competitive pressures in core markets, and the long-term impact of patent expirations on major revenue drivers.

Geopolitical and regulatory uncertainties also pose challenges to global operations.

Competitive Landscape

AstraZeneca competes at the top tier of global pharma against giants like Pfizer, Merck, and Roche. Its competitive advantages include a deep and broad pipeline, global commercial scale, and leading-edge integration of AI and novel therapeutic platforms, though it faces intense battles in key drug classes like oncology ADCs and metabolic therapies.